Table 1 Clinicopathological and sequencing characteristics
From: Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling
Clinicopathological characteristics | ||
Characteristic | Discovery cohort | Validation cohort |
Patients, N | 94 | 24 |
Tissue samples, N | 106 | 24 |
Age at RP, median (range) | 65.7 (45.7–76.6) | N/A |
Tumor status | ||
Benign, N (%) | 23 (21.7%) | 8 (33.3%) |
Malignant, N (%) | 83 (78.3%) | 16 (66.6%) |
Pathological Gleason score | ||
≤ 7, N (%) | 63 (75.9%) | 9 (56.2) |
> 7, N (%) | 20 (24.1%) | 7 (43.7) |
Pre-operative PSA (ng/ml) | ||
≤ 10, N (%) | 39 (47%) | N/A |
>10, N (%) | 39 (47%) | N/A |
Unknown, N (%) | 5 (6%) | N/A |
Pathological T-stage | ||
pT2, N (%) | 51 (61.4%) | 4 (25%) |
pT3, N (%) | 31 (37.4%) | 10 (62.5%) |
Unknown/pT4, N (%) | 1 (1.2%) | 2 (12.5%) |
Biochemical recurrence status | ||
BCR, N (%) | 28 (33.7%) | 6 (37.5%) |
BCR-free, N (%) | 53 (63.9%) | 10 (62.5%) |
Unknown, N (%) | 2 (2.4%) | -- |
Median follow-up, months (range) | 52.4 (17.6–178.9) | N/A |
Sequencing characteristics | ||
Characteristic | Discovery Cohort | Validation cohort |
Total reads in bam per sample, mean (SD) | 76,688,094 (11,296,752) | 304,920,301 (49,502,192) |
Reads per sample mapped to hg38, mean (SD) | 60,131,687 (7,869,239) | 170,390,820 (16,853,739) |
Unmapped read pairs per sample, mean (SD) | 970,526 (280,812) | 2,734,147 (421,428) |